Cartilage extracellular matrix biosynthesis

Cartilage extracellular matrix (ECM) biosynthesis is a complex biological process primarily carried out by chondrocytes to maintain the structural integrity and mechanical properties of cartilage tissue. This process involves the coordinated expression and assembly of key macromolecules, including type II collagen, aggrecan, and various glycosaminoglycans, which provide the tissue with tensile strength and compressive resilience (Source: Gene Ontology GO:0001502). In degenerative conditions like osteoarthritis, the balance between ECM synthesis and degradation is disrupted, leading to progressive tissue loss. While not a single molecular target, this biosynthetic pathway is a major focus of regenerative medicine and disease-modifying osteoarthritis drugs (DMOADs), which aim to stimulate anabolic activity through growth factors like FGF18 or by inhibiting catabolic signaling (Source: PubMed PMC6055514). Therapeutic strategies often target specific regulators within this process, such as SOX9 or TGF-beta signaling, to restore healthy matrix production.

Other names

Chondrocyte extracellular matrix synthesisCartilage ECM productionCartilage matrix biosynthesis

Modulation of anabolic signaling pathways (e.g., FGF18, Wnt signaling) or provision of metabolic precursors to stimulate the production of collagen type II and aggrecan by chondrocytes.